Enterprise Value
-17.98M
Cash
203.1M
Avg Qtr Burn
-23.32M
Short % of Float
14.87%
Insider Ownership
0.84%
Institutional Own.
81.16%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MRT-2359 Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Data readout |